Compare OPHC & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPHC | SCYX |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | United States |
| Employees | 98 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 60.4M |
| IPO Year | 2012 | 2014 |
| Metric | OPHC | SCYX |
|---|---|---|
| Price | $5.46 | $4.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.50 | $3.00 |
| AVG Volume (30 Days) | 21.4K | ★ 354.4K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ 0.20 | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | $17,095.98 | N/A |
| Revenue Next Year | N/A | $608.78 |
| P/E Ratio | $27.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.91 | $0.57 |
| 52 Week High | $5.64 | $5.62 |
| Indicator | OPHC | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 79.82 |
| Support Level | $5.40 | $0.67 |
| Resistance Level | $5.60 | N/A |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | -0.01 | 0.48 |
| Stochastic Oscillator | 84.76 | 81.15 |
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides community banking services to individuals and corporate customers. The services provided by the bank include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal accounts, borrowings, repayment of loans, money market deposit accounts, debit cards, automated teller machines, and other bank related services.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.